National Institutes of Health: Carcinoma, Renal Cell trials

The registry lists 123 Carcinoma, Renal Cell studies with National Institutes of Health as lead sponsor. 10 are open to participants now and 50 have results posted.

Phase 1 44Phase 2 79Phase 3 7No phase 7(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) CancerCompletedNCT00083109Phase 1/2
• Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00082914Phase 2
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell CancerCompletedNCT00060307Phase 2
• Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell CancerCompletedNCT00059813Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell CancerCompletedNCT00057889Phase 2
• Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney CancerCompletedNCT00032188Phase 2
• Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug ResistanceCompletedNCT00026663
• Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerCompletedNCT00020540Phase 1
• Radiofrequency Interstitial Tissue Ablation in Treating Patients With Localized Renal Cell Carcinoma (Kidney Cancer)CompletedNCT00019955Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney CancerCompletedNCT00019539Phase 2
• flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell CancerCompletedNCT00019396Phase 2
• Interleukin-2 in Treating Patients With Metastatic Kidney CancerCompletedNCT00018941Phase 3
• SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous TreatmentTerminatedNCT00009919Phase 2
• Carboxyamidotriazole in Treating Patients With Metastatic Kidney CancerCompletedNCT00006486Phase 2
• Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNAStatus unknownNCT00006431Phase 1
• Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant MelanomaCompletedNCT00004244Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Bryostatin 1 in Treating Patients With Metastatic Kidney CancerCompletedNCT00003968Phase 2
• Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney CancerCompletedNCT00003553Phase 2
• Lymphocyte Therapy in Treating Patients With Kidney CancerStatus unknownNCT00002589Phase 2
• A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic CancerCompletedNCT00001683Phase 1
• A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833CompletedNCT00001383Phase 1